Published in Cancer Weekly, January 21st, 2003
APP expects to begin marketing vincristine as well as kanamycin in 2003.
"Vincristine and kanamycin add further breadth to our oncology and anti-infective product offerings and brings to 12 the number of FDA approvals APP has received in 2002," said Patrick...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.